Bergen 29 June 2023: Reference is made to previous stock exchange announcements
from BerGenBio ASA ("BerGenBio" or the "Company") regarding the partially
underwritten rights issue of up to 2,500,000,000 new shares (the "Offer Shares")
in the Company, raising gross proceeds of up to NOK 250 million (the "Rights
Issue"). Reference is further made to the stock exchange notice published on 27
June 2023 regarding a resolution to increase the share capital for settlement of
parts of the underwriting commission through the issuance of 31,872,000 new
shares (the "Fee Shares") to certain underwriters of the Rights Issue.

The share capital increases relating to the issuance of the Fee Shares have now
been registered with the Norwegian Register of Business Enterprises. The share
capital has been increased with NOK 3,187,200 through the issuance of 31,872,000
new shares.

The new share capital is NOK 262,053,253.20 divided into 2,620,532,532 shares,
each with a par value of NOK 0.10.

The Fee Shares are expected to be delivered to the underwriters on or about 30
June 2023.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK.

The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the Oslo
Rule Book II and is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.